Clinical Trials
76
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (59 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: PlaceboDrug: (Part B) MKND-201Drug: (Part A) MKND-201
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT06532942
- Locations
- 🇺🇸
Flourish Research, San Antonio, Texas, United States
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
- Conditions
- Treatment Refractory MAC Lung DiseaseMAC Lung DiseaseMycobacterium Infections, Nontuberculous
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 234
- Registration Number
- NCT06418711
- Locations
- 🇺🇸
University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
🇺🇸University of California San Francisco Fresno, Fresno, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
- Conditions
- Diabetes Mellitus, Type 1
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 141
- Registration Number
- NCT05904743
- Locations
- 🇺🇸
Loma Linda University-Diabetes Treatment Center, Loma Linda, California, United States
🇺🇸Sansum Diabetes Research, Santa Barbara, California, United States
🇺🇸Barbara Davis Center, Aurora, Colorado, United States
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
- Conditions
- Type 1 Diabetes
- Interventions
- Device: Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 33
- Registration Number
- NCT05243628
- Locations
- 🇺🇸
Diabetes Treatment Center, Loma Linda University, Loma Linda, California, United States
🇺🇸Texas Diabetes and Endocrinology, Austin, Texas, United States
Afrezza® INHALE-1 Study in Pediatrics
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 319
- Registration Number
- NCT04974528
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
MannKind Prepares to Present Pediatric Inhaled Insulin Data at ADA Scientific Sessions
MannKind Corporation will showcase results from its Phase 3 INHALE-1 clinical trial of Afrezza inhaled insulin in children and adolescents aged 4-17 at the American Diabetes Association's 85th Scientific Sessions in Chicago.
Inhaled Insulin Shows Promising Results in Type 1 Diabetes Management Over 30 Weeks
INHALE-3 trial data reveals that 74% of adults with type 1 diabetes increased their technosphere insulin (Afrezza) dose by more than 4 units over 30 weeks, with total daily doses rising from 36 to 52 units.
MannKind Initiates Phase 3 Trial of Clofazimine Inhalation Suspension for NTM Lung Disease
MannKind Corporation has started its Phase 3 ICoN-1 trial to assess Clofazimine Inhalation Suspension for treating nontuberculous mycobacterial (NTM) lung disease.